pritchettpolicy.bsky.social
@pritchettpolicy.bsky.social
Founder, Pritchett Policy Associates
Senior Associate, Center for Strategic & International Studies
Innovation policies, biopharma supply chain, US leadership, US competitiveness, STEM, cybersecurity, advance manufacturing, technology transfer, trade
Vaccine safety: Data from more than 30 primary research studies across multiple countries debunk the allegation that there is any link between autism and vaccines AND "strongly supports the positive safety profile of vaccines used during childhood and pregnancy."
www.who.int/news/item/11...
WHO expert group’s new analysis reaffirms there is no link between vaccines and autism
New analysis from a WHO global expert committee on vaccine safety has found that, based on available evidence, no causal link exists between vaccines and autism spectrum disorders (ASD). The conclusio...
www.who.int
January 14, 2026 at 8:30 PM
New piece from my colleagues at CSIS on how university patents shape U.S. competitiveness in tech, health, and national security & why we need to reject proposals that would undermine our tech transfer system and seize patent royalties from universities. Read it here: www.csis.org/analysis/uni...
Universities, Patents, and the Future of U.S. Competitiveness
The strength of the United States’ innovation system does not rest on government spending alone, but on the mutually supportive partnership between public investment, university research, and private ...
www.csis.org
January 14, 2026 at 8:20 PM
Read my commentary to learn more about how PTO Director Squires is sending a powerful signal that America is a welcome home to innovation by clarifying which inventions are patent eligible & restoring procedural fairness at PTAB. dcjournal.com/a-stronger-p...
A Stronger Patent System Means a Stronger America – DC Journal - InsideSources
Imagine founding a startup and working for years to research and develop a groundbreaking new product, only to have your invention stolen by another
dcjournal.com
January 14, 2026 at 7:34 PM
Read my new commentary raising concerns on the impacts of MFN drug pricing policy on innovation and the socioeconomic benefits that accrue to U.S. patients and the U.S. economy from biopharma investments. www.csis.org/analysis/sec...
Securing the Future of the U.S. Biopharmaceutical Industry: The Most-Favored-Nation Paradox
The administration’s success in securing massive investment pledges from the industry to reshore manufacturing needs to be reinforced. Its positive impact will be undermined if the long-term consequen...
www.csis.org
January 14, 2026 at 7:24 PM
Oppose cuts to Medicaid to protect your loved ones

You or a loved one could be one fall away from a brain injury that will quickly exhaust finances. Medicaid is the single largest source for long-term care for disabled and elderly people, paying 60% of the nation's extended nursing-home stays.
June 21, 2025 at 2:40 PM